15th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals
22nd — 24th April 2024
Lisbon, Portugal
We look forward to seeing you in Lisbon for another great conference.
Hotel accommodation
Altis Grand Hotel
The conference venue. Special rates have been negotiated for conference attendees. Please book via the link for these rates to be applied.
Rua Castilho 11
1269-072 Lisboa
Portugal
Ibis Lisboa Centro Liberdade
Just next door to the conference venue, a 2 minute walk.
Rua Barata Salgueiro 53
1250-043 Lisboa
Portugal
GPS:38.720182, -9.150316
Avani Avenida Liberdade Lisbon Hotel
A 10 minute walk to the conference venue.
Rua Júlio César Machado 7/9
1250-135 Lisboa
Portugal
GPS: 38.720430, -9.147490
Ibis Styles Lisboa Centro Marquês de Pombal
A 15 minute walk to the conference venue.
Av. Fontes Pereira de Melo 5
1069-114 Lisboa
Portugal
Sponsoring opportunities
Our annual symposium is the perfect place for your organisation to promote your products and services to an audience of scientific experts active in the area of immunogenicity. The sponsor package includes:
- a booth at the conference hotel
- a free page in the brochure containing the conference agenda
- free entrance to the meeting for 2 delegates from your company
- full access to the conference including the scientific presentations
- two free invitations to the social event
Package prices:
- for members of the European Immunogenicity Platform: 5,000 €
- for non-members of the European Immunogenicity Platform: 10,000 €
Please email Barbara Vercruyssen if you wish to sponsor the event
After registering as a sponsor, you will receive an invoice. Upon settlement of this invoice, the sponsoring is accepted. The next step is then to provide us with:
- Your company details and contact person’s name, phone number and email address
- A visual (photo/image/logo) from your organisation
- The URL of your website
- An optional YouTube embed URL
Logistics:
- Deadline for material submission: 15th March 2024
- Deadline for delivery of booth material to site: 1st April 2024
- Material to be shipped to: Altis Grand Hotel, R. Castilho 11, 1269-072 Lisboa, Portugal
- Phone: +351 21 310 6000
- For the attention of: Claudia
- Conference: EIP, 22-24, 2024 (contact: Barbara Vercruyssen)
Click here to download a PDF with details of the sponsoring package
The deadline for sponsoring is 31st January 2024
Program
Wednesday, April 22nd 2024 |
||||
| Workshop Day | ||||
| 09:00 | Coming Together | |||
| Immunogenicity Risk Assessment | ||||
| 09:15 |
Consolidated EIP Proposal for Immunogenicity Risk Assessment Veerle Snoeck, Joanna Grudzinska Goebel on behalf of EIP |
|||
| 10:15 | Coffee Break | |||
| In-silico and in-vitro Assays as Part of the Immunogenicity Risk Assessment | ||||
| 10:45 |
Immunogenicity potential assessment at Novartis Anette Karle, Novartis |
|||
| 11:15 |
Immunogenicity potential assessment at Pfizer Sophie Tourdot, Pfizer |
|||
| 11:45 |
Design and Implementation of a Risk-Based Strategy for Reducing Immunogenicity Risk of Protein Therapeutics Karen Heyninck (to be confirmed), Sanofi |
|||
| 12:15 | Lunch | |||
| 13:30 |
Bring Your own Problems (Breakout Sessions) Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Sofie Pattijn, ImmunXperts Sophie Tourdot, Pfizer Veerle Snoeck, UCB Tim Hickling, Roche Lydia Michaut, Novartis |
|||
| 15:00 | Coffee Break | |||
| 15:30 | Continue “Bring Your own Problems (Breakout Sessions)” | |||
| 16:30 | Closing of the Workshop Day | |||
| 17:00 – 18:30 |
Meeting of the EIP Working Groups Members of EIP working groups |
|||
Thursday, April 23rd 2024 |
||||
| 09:00 |
Welcome and Introduction by the EIP Chairman Daniel Kramer, Sanofi |
|||
| 09:15 |
Spotlight Presentations: MHC Class I and its Importance for the Immunogenicity of Novel Modalities Morten Nielsen, Technical University of Denmark Zuben Sauna, FDA |
|||
|
Session 2: Prediction of Immunogenicity Chair: Sebastian Spindeldreher |
||||
| 10:15 |
EIP NCIRA Working Group Update Sebastian Spindeldreher, Integrated Biologix on behalf of EIP |
|||
| 10:30 |
Immunogenicity: It’s Personal Annie de Groot, EpiVax |
|||
| 11:00 | Coffee Break | |||
|
Short Talks (15 minutes each) |
||||
| 11:30 |
High-Sensitive MAPPS Analysis for High-Confident Immunogenicity Risk Assessment Elise Pepermans, ImmuneSpec |
|||
| 11:45 |
Expanding the MAPPs Assay to MHC-II-DR, -DP and –DQ Receptors Axel Ducret, Roche |
|||
| 12:00 |
Immunogenicity of Therapeutic Antibodies: Role of Aggregation in T Lymphocyte Response Marc Pallardy, INSERM |
|||
| 12:15 | Lunch Break | |||
| 13:30 |
QSP Modeling Immunogenicity: Predicting the Efficacy of Methotrexate in Decreasing Incidence and Prevalence of Anti-Drug Antibodies Catherine Weathered, Pfizer |
|||
| 14:00 |
Naive and Memory FVIII-Specific Regulatory and Conventional CD4 T Cells Share Common Epitopes in Healthy Individuals Bernard Maillere, CEA |
|||
|
Session 3: Immunogenicity Assays Chair: Veerle Snoeck |
||||
| 14:30 |
EIP Immunogenicity Assays Working Group Update Linlin Luo, Merck Sharp & Dome on behalf of EIP |
|||
| 14:45 | Coffee Break | |||
| 15:15 |
Domain Characterization of Bi-specifics in the ADA and in the NAb Assay Issa Jyamubandi, Resolian Bioanalytics |
|||
| 15:45 |
Case study: Developing an ADA assay with enhanced Free Drug Tolerance for Octreotide René Wuttke, Debiopharm |
|||
| 16:15 |
Phase-appropriate implementation of a domain specificity strategy Matthias Reichel, BioAgilytix |
|||
| 16:45 |
The IVDR and its Impact on Clinical Immunogenicity Assay Development Robert Nelson, BioAgilytix |
|||
|
Session 3: Social Event Chair: Barbara Vercruyssen |
||||
| 18:00 | Get Together | |||
| 23:00 | Good Night | |||
Friday, April 24th 2024 |
||||
|
Session 4: Immunogenicity of New Modalities Chair: Arno Kromminga |
||||
| 09:00 |
Development of an ELISpot Assay for the Assessment of AAV Peptides to Examine Immune Safety Alison Johnson, Boehringer Ingelheim |
|||
| 09:30 |
Immunogenicity Risk Assessment for mRNA/LNP Therapies Joanna Grudzinska Goebel, Bayer |
|||
| 10:00 |
Total or Neutralizing Antibodies Against Adeno-Associated Virus, What is the Best Sabrina Lory, UCB |
|||
| 10:30 |
Orthogonal Approach for AAV Immunogenicity Assessment: Evaluating Total and Neutralizing Antibodies Anna Karaszewska (to be confirmed), SVAR |
|||
| 11:00 | Coffee Break | |||
|
Session 5: Clinical Relevance of Immunogenicity Chair: Lydia Michaut |
||||
| 11:30 |
Overcoming Magic Bullet Approaches for Immune Tolerance Induction for Complex Diseases: Application to Immunogenicity of Biological Therapeutics Amy Rosenberg, EpiVax |
|||
| 12:00 |
ADA Monitoring Strategy for Repetitive High Doses of Biologics Therapies: Efficiently Integrating Scientific, Technical, and Regulatory Aspects Maria Jadhav, Novartis |
|||
| 12:30 |
The Wonderful World of Immunogenicity; Scientific Understanding, Clinical Relevance, and Regulatory Necessity Floris Loeff, Sanquin |
|||
| 13:00 | Lunch Break | |||
|
Short Talks (15 minutes each) |
||||
| 14:15 |
Drug T Cell Reactivity in Delayed Type Hypersensitivity – Evaluation with Cyto-LTT Lester Thoo, ADR-AC |
|||
| 14:30 |
Evaluating Immediate Type Drug Allergy and Immunostimulation in Vitro with the Basophil Activation Test (BAT) Daniel Yerli, ADR-AC |
|||
|
Session 6: Regulatory Chair: Daniel Kramer |
||||
| 14:45 | To be determined | |||
| 15:30 | To be determined | |||
| 16:00 |
Conference Summary & Outlook by the EIP Chairman Daniel Kramer, Sanofi |
|||
| 16:15 | Close of the conference | |||